Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | PLK1 | P53350 | 1/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | TNFSF11 | O14788 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27958054 | 0.91 | MEN1 (0.83) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL12344895 | 0.86 | KMT2A (0.76) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL28207078 | 0.86 | KMT2A (0.76) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL17422835 | 0.85 | KMT2A (0.73) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL2887226 | 0.85 | MEN1 (0.73) | KMT2AMEN1HTR6 | |
| SCHEMBL949716 | 0.84 | LMNA (1.00) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL30393652 | 0.84 | LMNA (1.00) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL8600630 | 0.84 | MEN1 (0.72) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL948989 | 0.84 | AKR1C3 (0.83) | KMT2AMEN1LMNASMN1; SMN2PLK1 | |
| SCHEMBL4784564 | 0.84 | MEN1 (0.72) | KMT2AMEN1LMNASMN1; SMN2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| CN-101501038-B | Fused [d]pyridazin-7-ones | CEPHALON INC | 2012-07-18 | — | — | CN | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| CN-101501038-A | Fused [d]pyridazin-7-ones | CEPHALON INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2035429-A1 | FUSED [d]PYRIDAZIN-7-ONES | Cephalon, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149557-A1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | KMT2A 1711/4885MEN1 2202/4885LMNA 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.